All In Biotech

NDA 020334 · Pfizer

Flagyl

Metronidazole · Oral · Nitroimidazole Antimicrobial

Last checked: Nov 19, 2026Latest source record: Jul 8, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

May 3, 1995

Approved uses

1

Original approval plus efficacy supplements

Registered trials

728

132 Phase 3, 52 recruiting

FAERS reports

63,834

53,748 serious, 6,909 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING Metronidazole has been shown to be carcinogenic in mice and rats (see PRECAUTIONS ). Unnecessary use of the drug should be avoided. Its use should be reserved for the conditions described in the INDICATIONS AND USAGE section below.

What it is approved for

From the label in effect May 22, 2026.

INDICATIONS AND USAGE Symptomatic Trichomoniasis . FLAGYL 375 capsules are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis . FLAGYL 375 capsules are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Sexual Partners . T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the sexual partner should be treated with metronidazole in cases of reinfection. Amebiasis . FLAGYL 375 capsules are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, FLAGYL 375 capsules therapy does not obviate the need for aspiration or drainage of pus....

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 3, 1995 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • FLAGYL · METRONIDAZOLE 375MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Metronidazole" as an intervention, any sponsor and status, largest first.

All 728 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective5,512
  • nausea4,677
  • off label use4,209
  • diarrhoea4,084
  • vomiting3,308
  • pyrexia3,224
  • drug hypersensitivity3,164
  • pain3,035
  • abdominal pain3,004
  • headache2,880
  • fatigue2,803
  • dyspnoea2,244

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004768
2005819
2006874
2007887
2008767
20091,179
20101,432
20111,903
20122,383
20132,164
20142,426
20153,273
20163,757
20173,481
20185,261
20195,610
20204,735
20214,501
20223,972
20233,936
20243,586
20253,743
20262,373

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Flagyl (Metronidazole)

2024 spending

$994

Beneficiaries

n/a

11 claims

Per beneficiary

n/a

$6.45 per unit

View as table
YearSpending
2020$3,880
2021$2,643
2022$0
2023$0
2024$994

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,038 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.